Ongoing safety review of sibutramine, marketed as Reductil, to make public within this week
Published: 2010-07-20 07:00:00
Updated: 2010-07-20 07:00:00
The Korea Food and Drug Administration has reviewed additional data that indicate an increased risk of heart attack and stroke in patients with a history of cardiovascular disease using sibutramine, marketed as the weight loss medication Reductil.
Sibutramine is a centrally acting stimulant c...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
